Skip to main content

Table 1 Demographics of patients with Pseudomonas aeruginosa bacteraemia

From: The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study

 

All patients

(n = 128)

+IDC

(n = 91)

-IDC

(n = 37)

P Value

Age (years): Median

68

62

66

0.203

IQR

59–78

43–75

47–77

Male: n (%)

69 (53.9)

51 (56.0)

18 (48.6)

0.572

Comorbidities and medical history: n (%)

 Charlson comorbidity index (severe, score ≥ 5)

78 (60.9)

50 (54.9)

28 (75.7)

0.048

 Haematological malignancy

46 (35.9)

35 (38.5)

11 (29.7)

0.465

 Solid organ tumour

28 (21.9)

18 (19.8)

10 (27.0)

0.507

 Diabetes

22 (17.2)

13 (14.3)

9 (24.3)

0.269

 Liver cirrhosis

15 (11.7)

12 (13.2)

3 (8.1)

0.612

 Renal insufficiency

25 (19.5)

20 (22.0)

5 (13.5)

0.396

 Heart failure

9 (7.0)

4 (4.4)

5 (13.5)

0.148

 Immunosuppressed

86 (67.2)

59 (64.8)

27 (73.0)

0.496

Admitting Teams: n (%)

   

0.455

 Hematology

48 (37.5)

36 (39.6)

12 (32.4)

 General medicine

31 (24.2)

19 (20.9)

12 (32.4)

 Medical oncology

26 (20.3)

18 (19.8)

8 (21.6)

 Renal medicine

5 (3.9)

3 (3.3)

2 (5.4)

 Urology

5 (3.9)

5 (5.5)

0 (0)

 Other a

13 (10.2)

9 (9.9)

4 (10.8)

  1. Abbreviations: IQR interquartile range, +IDC received infectious diseases specialist consultation, −IDC did not receive infectious diseases specialist consultation
  2. a Other group includes General surgery, Gastroenterology, Cardiology, Cardiothoracic, Neurology, Orthopaedics, Radiation Oncology and Vascular teams